YiChang HEC ChangJiang Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Juncai Jiang
Chief executive officer
CN¥1.3m
Total compensation
| CEO salary percentage | 47.1% |
| CEO tenure | 9yrs |
| CEO ownership | 0.008% |
| Management average tenure | 6.8yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥608m |
| Dec 31 2022 | CN¥1m | CN¥600k | CN¥77m |
| Sep 30 2022 | n/a | n/a | -CN¥18m |
| Jun 30 2022 | n/a | n/a | -CN¥113m |
| Mar 31 2022 | n/a | n/a | -CN¥351m |
| Dec 31 2021 | CN¥1m | CN¥490k | -CN¥588m |
| Sep 30 2021 | n/a | n/a | -CN¥436m |
| Jun 30 2021 | n/a | n/a | -CN¥285m |
| Mar 31 2021 | n/a | n/a | CN¥277m |
| Dec 31 2020 | CN¥756k | CN¥229k | CN¥839m |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥2b |
| Dec 31 2019 | CN¥393k | CN¥222k | CN¥2b |
| Sep 30 2019 | n/a | n/a | CN¥2b |
| Jun 30 2019 | n/a | n/a | CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥1b |
| Dec 31 2018 | CN¥365k | CN¥209k | CN¥943m |
| Sep 30 2018 | n/a | n/a | CN¥961m |
| Jun 30 2018 | n/a | n/a | CN¥980m |
| Mar 31 2018 | n/a | n/a | CN¥813m |
| Dec 31 2017 | CN¥324k | CN¥194k | CN¥647m |
Compensation vs Market: Juncai's total compensation ($USD175.94K) is below average for companies of similar size in the Hong Kong market ($USD552.49K).
Compensation vs Earnings: Juncai's compensation has increased by more than 20% in the past year.
CEO
Juncai Jiang (41 yo)
9yrs
Tenure
CN¥1,274,000
Compensation
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 9yrs | CN¥1.27m | 0.0076% CN¥ 865.6k | |
| CFO & Head of Finance Department | 5.3yrs | CN¥480.38k | no data | |
| Head of the Sales Department | 10yrs | CN¥1.03m | 0.0076% CN¥ 861.0k | |
| Deputy GM & Executive Director | 9yrs | CN¥917.00k | 0.0076% CN¥ 871.3k | |
| Deputy GM & Executive Director | 9yrs | CN¥798.00k | 0.0076% CN¥ 865.6k | |
| Joint Company Secretary | 5.6yrs | CN¥370.31k | no data | |
| Chief of Quality Division & Employee Representative Supervisor | 6.8yrs | no data | 0.0036% CN¥ 415.1k | |
| Executive Director | less than a year | no data | no data | |
| Joint Company Secretary | 2.3yrs | no data | no data |
6.8yrs
Average Tenure
42yo
Average Age
Experienced Management: 1558's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 9yrs | CN¥1.27m | 0.0076% CN¥ 865.6k | |
| Deputy GM & Executive Director | 18.3yrs | CN¥917.00k | 0.0076% CN¥ 871.3k | |
| Deputy GM & Executive Director | 5.9yrs | CN¥798.00k | 0.0076% CN¥ 865.6k | |
| Chief of Quality Division & Employee Representative Supervisor | 6.8yrs | no data | 0.0036% CN¥ 415.1k | |
| Executive Director | less than a year | no data | no data | |
| Non-Executive Chairman | 9yrs | no data | 0.015% CN¥ 1.7m | |
| Independent Non-Executive Director | 9yrs | CN¥100.00k | no data | |
| Supervisor | 6.9yrs | no data | 0.0076% CN¥ 865.6k | |
| Chairman of the Board of Supervisors | 4.9yrs | no data | no data | |
| Independent Non Executive Director | 3.9yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 3.7yrs | CN¥340.00k | 0.00045% CN¥ 51.3k |
6.8yrs
Average Tenure
43.5yo
Average Age
Experienced Board: 1558's board of directors are considered experienced (6.8 years average tenure).